-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Seizing Opportunities and Stepping Up to the Plate: Charging Ahead with Determination—A Series of Highlight Reports on Shijiazhuang Sihua Pharmaceutical Group’s Achievements in High-Quality Development (Part One)
Category:
Time：2022-08-12
Shijiazhuang No.4 Pharmaceutical Group actively responds to the call of the Municipal Party Committee and the Municipal Government, seizes development opportunities, and strengthens its sense of responsibility. Guided by the goal of ensuring smooth dual circulation in both domestic and international markets, the group leverages its comparative advantages, builds competitive strengths, and achieves remarkable economic and social benefits, consistently delivering impressive performance results.
In Shijiazhuang in August, everything is lush and green, and everywhere exudes an atmosphere of vigorous momentum and boundless energy.
Yang Liyan, a veteran employee of Shijiazhuang No.4 Pharmaceutical Group who has been with the company for 32 years, has personally witnessed one new project after another “take root and blossom” within her own enterprise, as well as one new product after another receiving approval. She can’t help but express her heartfelt admiration: “Our Shijiazhuang biopharmaceutical industry is now experiencing an unprecedentedly golden opportunity for development. I’m confident that our company’s future will be even brighter!”
Where does this “confidence” come from? It comes from here—
Since the 11th Municipal Party Congress, the Municipal Party Committee and the Municipal Government have consistently and comprehensively implemented the new development philosophy in a thorough, accurate, and holistic manner. They have vigorously promoted the biomedical industry to achieve breakthroughs ahead of others and are working hard to build a biomedical industry cluster worth hundreds of billions of yuan. The Municipal Party Committee and the Municipal Government have issued the "Several Measures (Trial) for Supporting the Pioneering Breakthroughs of the Next-Generation Electronic Information Industry and the Biomedical Industry," providing a range of support measures for the biomedical industry’s pioneering development, including establishing leading-industry development funds and special funding support, rewarding R&D innovation and technology transfer, facilitating project construction, encouraging expansion into domestic and international markets, supporting the construction of major projects, cultivating competitive enterprises, reducing burdens on businesses, and strengthening incentives for high-end talent. All levels and departments have continuously optimized the business environment, provided attentive services to enterprises, and given businesses a powerful “boost” to accelerate their growth.
As a key enterprise in the city’s biopharmaceutical industry, Shijiazhuang Sihua Pharmaceutical Group has actively responded to the call of the Municipal Party Committee and Municipal Government, seized development opportunities, strengthened its sense of responsibility, and, guided by the goal of smoothing the dual circulation of domestic and international markets, leveraged its comparative advantages to build competitive strengths, achieving remarkable economic and social benefits and consistently delivering impressive performance.
In the first half of this year, Shijiazhuang No.4 Pharmaceutical Group achieved a total industrial output value of 3.78 billion yuan, representing a year-on-year increase of 52.6%. Profits and taxes saw a substantial rise, with tax payments reaching 280 million yuan, up 16.7% over the same period last year. The company has made new breakthroughs in its development and is now at the forefront of pharmaceutical enterprises both in the city and the province.
Right now, Shijiazhuang No.4 Pharmaceutical is aiming to achieve sales revenue of 20 billion yuan by the end of the 14th Five-Year Plan period, “speeding up” on the path of high-quality development and striving to be a frontrunner in driving the city’s biopharmaceutical industry to achieve breakthroughs ahead of others.
“Juejin”’s distinctive and advantageous products Accelerate the move toward the high-end of the value chain.
Products are the “cornerstone” of a company, and high-quality, high-value-added products are the source of its profitability.
As the “leading player” in China’s large-volume parenteral solutions industry, Shijiazhuang No.4 Pharmaceutical Company is widely renowned. However, confronted with new market dynamics, the company’s decision-makers are keenly aware of the limitations inherent in being overly reliant on a single business segment and have resolutely embarked on a path to break out of their existing boundaries and achieve broader growth. In light of the company’s actual situation, Shijiazhuang No.4 Pharmaceutical actively implements the requirements put forth by the municipal Party committee and municipal government to further build, extend, supplement, and strengthen industrial chains. By leveraging the group’s comprehensive advantages—including raw materials, talent, technology, and financial resources—Shijiazhuang No.4 Pharmaceutical is firmly committed to aligning its industrial chain around the innovation chain and deploying the innovation chain around the industrial chain, thereby accelerating its transition toward the mid-to-high end of the value chain.
At the formulation production facility of Shijiazhuang No.4 Pharmaceutical, located in the High-tech Zone, reporters not only saw traditional “large-volume infusions” in multiple specifications but also a variety of new “small-volume injections.”
In the 104 Water Injection Preparation Workshop, 2-milliliter betahistine hydrochloride injection is currently being produced. “This is one of our company’s star products that generates significant value. It’s manufactured using a sterile preparation process and boasts high added value, earning widespread acclaim from the market,” said Wang Chao, the workshop supervisor, with pride.
Focusing on the market’s most in-demand and urgent product categories, Shijiazhuang Fourth Pharmaceutical is making strategic investments in areas such as antiviral, antibacterial, anti-tumor, nervous system, cardiovascular, digestive, and anesthetic therapies. The company is also actively developing new dosage forms—including aqueous injections, emulsions, lyophilized products, microspheres, liposomes, dual-chamber bags, multi-chamber bags, and powder-liquid multi-chamber bags—striving to establish a leading edge in advanced drug delivery systems and innovative packaging solutions. Currently, Shijiazhuang Fourth Pharmaceutical has 195 products in development and has submitted 119 products for approval.
The upstream of pharmaceutical formulations is the active pharmaceutical ingredient (API), which is also crucial to formulation production. Only by firmly securing control over the API can we avoid being “choked” or constrained. To extend its industrial chain, Shijiazhuang Fourth Pharmaceutical is focusing on specialty APIs that are urgently needed by the market and highly valuable. Currently, it offers 31 such products, and its team continues to grow steadily.
Currently, Shijiazhuang Sihua Pharmaceutical Group has 10 subsidiaries and assets totaling 9 billion yuan. The group has established a comprehensive industrial chain covering the entire value chain—from the R&D and production of specialty APIs and novel formulations to innovative drugs, as well as pharmaceutical packaging materials, their development, and application.
The continuous optimization of product structures and the ongoing refinement of the industrial chain are injecting vibrant momentum into the high-quality development of Shijiazhuang Fourth Pharmaceutical. Currently, more than 80% of its profits are generated by new products or upgraded products.
11 high-quality projects “team up” to sprint toward the finish line. Accumulate new momentum for high-quality development.
Today’s “major projects” are tomorrow’s “great developments.”
For the city’s biopharmaceutical industry to achieve a pioneering breakthrough, it must be supported by a large number of major and high-quality projects that continuously inject new momentum.
Shijiazhuang Fourth Pharmaceutical is focusing on “specialization, refinement, uniqueness, and innovation” in the biopharmaceutical sector. It closely integrates its product and market positioning—“only by entering the high-end market can we secure a future”—with its development philosophy of “projects are paramount,” and is putting this approach into action.
Tower cranes, excavators, and loaders are working at full speed... At the construction site of Shijiazhuang Siyao’s new formulation and biopharmaceutical industrial park—a key provincial and municipal project—construction is in full swing. “Our project adopts EU design principles and is meticulously crafted to be a high-standard, high-quality model project with an international outlook. Currently, the project is more than halfway complete, and we expect it to be fully completed and operational by June 2023. Once operational, its output value will reach 2.7 billion yuan, generating 800 million yuan in profits and taxes. This project is one of the key strategic pillars that will help our company surpass the 20-billion-yuan mark in sales revenue by the end of the 14th Five-Year Plan period,” said Zhao Yongzheng, Executive President of Shijiazhuang Siyao Group and Chairman of Hebei Guolong Pharmaceutical, who almost daily “keeps a close eye” on the construction site.
Since last year, 11 new and ongoing projects—including production lines for lyophilized powder injections, emulsions, dry suspensions, novel pharmaceutical formulations, and peritoneal dialysis solutions—have commenced construction in Shijiazhuang High-tech Zone and Shijiazhuang Economic and Technological Development Zone, with a total investment of 2.15 billion yuan. Among these projects, the emulsion production workshop, which meets world-class standards, has nearly completed equipment installation and commissioning. Trial production is expected to begin in October, and once fully operational, its products will fill the gap in emulsion production within the province’s pharmaceutical industry, with annual sales revenue projected to exceed 500 million yuan.
By leveraging the leading role of projects in driving industrial development, we have demonstrated the high standards and innovative spirit inherent in project construction. At Shijiazhuang No.4 Pharmaceutical, each project is far from being a mere replication or copy-and-paste of existing plants, equipment, or processes. As Qu Jiguang, Chairman of the Board of Directors of Shijia No.4 Pharmaceutical Group, put it: “Every project must reflect the latest achievements in industrial development and strive to become a benchmark and model for industrial upgrading.”
One high-quality project after another is providing the solid “beams and pillars” that will support Shijiazhuang Fourth Pharmaceutical’s future high-quality development.
Focusing on the “dual circulation” and deepening market engagement. China’s domestic and international “circle of friends” continues to expand.
Even the aroma of fine wine can get lost in a narrow alley. A great product needs to find the “right buyer” to realize its full value and boost enterprise profitability.
2022 is a pivotal year for Shijiazhuang Fourth Pharmaceutical to achieve its goals for the 14th Five-Year Plan, and the market itself is the “key” to this pivotal year. To this end, Shijiazhuang Fourth Pharmaceutical has specially launched a “Marketing Breakthrough Offensive.”
At the Shijiazhuang Fourth Pharmaceutical Logistics Center, reporters saw forklifts shuttling back and forth, and container trucks fully loaded and ready to depart, presenting a bustling scene.
“Since last year, more than 40 newly approved drug varieties from Sihua Pharmaceutical have already entered production. Many of these new products boast compelling advantages in terms of indications, cost, and accessibility. For instance, our new products—such as terbutaline inhalation solution, ambroxol injection, doxofylline injection, and bromhexine injection—have become highly sought-after as soon as they hit the market, demonstrating tremendous market vitality and experiencing explosive sales growth. The upcoming launches of products like methylcobalamin injection and pentoxifylline injection will also serve as new drivers for the company’s sales growth,” said Zhen Zhanjun, Executive President of Shijiazhuang Sihua Pharmaceutical Group and General Manager of the Pharmaceuticals Division, with great enthusiasm to our reporter. As of now, a total of 35 product specifications across 26 varieties have successfully passed the national evaluation of consistency in quality and efficacy for generic drugs, while 11 product specifications across 8 varieties have been selected for the National Drug Procurement Program.
Since the beginning of this year, Shijiazhuang No.4 Pharmaceutical has focused on the “dual circulation” strategy and actively expanded both domestic and overseas markets, achieving sales growth against the trend. Even more encouragingly, having successively passed audit certifications from over 30 countries and international organizations, Shijiazhuang No.4 Pharmaceutical’s global marketing footprint has continued to expand. After careful and rigorous comparisons, many business partners from Europe, Southeast Asia, Africa, and other regions have extended olive branches to the company—precisely because they recognize the international quality that Shijiazhuang No.4 Pharmaceutical’s products possess. Today, Shijiazhuang No.4 Pharmaceutical’s customer network continues to grow, with its products now reaching across China and being sold in over 90 countries and regions.
Accumulate small steps, and you’ll reach a thousand miles.
“Treat yesterday as a thing of the past and regard today as a fresh starting point!” Su Xuejun, Chairman of Shijiazhuang No.4 Pharmaceutical Group, said with full confidence, “We must firmly seize the rare development environment and opportunities created by our city for pioneering breakthroughs in the biopharmaceutical industry. We’ll put even more pressure on ourselves, strive relentlessly to reach new heights, and ensure that by the end of the 14th Five-Year Plan, our core business revenue will exceed 20 billion yuan. We’re determined to join the top 30 Chinese pharmaceutical companies and the top 30 in terms of innovation capability, contributing our strength from Shijiazhuang No.4 Pharmaceutical Group to help our city’s economy surpass one trillion yuan and achieve a leapfrog development!”
“The development momentum of Shijiazhuang No.4 Pharmaceutical is truly encouraging. Even more valuable is the spirited attitude embodied by the company—the ‘jumping up to pick the peaches’ mindset—that deserves to be studied and adopted by more enterprises in our city,” said Huang Jinzhi, Deputy Director of the Municipal Bureau of Industry and Information Technology. He added that our city boasts strong foundational conditions for the biopharmaceutical industry. Promoting a breakthrough in the biopharmaceutical sector ahead of others and striving to build a trillion-yuan-level industrial cluster are strategic decisions made by the municipal Party committee and government after comprehensive consideration of the city’s industrial base, resource endowments, and development prospects. Thus, biopharmaceutical enterprises across the city bear a heavy responsibility. In particular, leading enterprises in various fields must fully leverage their role as pioneers and drivers, accelerate their growth and expansion, enhance their overall scale and competitiveness, and help our city’s biopharmaceutical industry reach the trillion-yuan mark at an early date.
Wu Shuke, a second-level researcher at the Municipal Development and Reform Commission, said that under the strong leadership of the Municipal Party Committee and the Municipal People's Government, the Municipal Development and Reform Commission has closely focused on the goal of achieving breakthroughs in the biopharmaceutical industry. It has promptly disbursed award and subsidy funds to Shijiazhuang Fourth Pharmaceutical in areas such as the industrialization of scientific research achievements, the development of new products, and major projects, thereby encouraging enterprises to step up their efforts in scientific research and innovation and accelerate project construction. This approach sets a benchmark and serves as a model for enterprises throughout the city, contributing to our city’s economic aggregate exceeding one trillion yuan.
Hao Hong'en, Director of the Economic Development Bureau of the High-tech Zone, said that under the strong leadership of the Municipal Party Committee and the Municipal Government, the High-tech Zone has established a dedicated task force to ensure the smooth implementation of the Shijiazhuang Siyao project, providing full support for land allocation for the company’s construction projects. The task force offers one-on-one, end-to-end assistance and targeted support, coordinates the provision of essential resources, and actively recommends Shijiazhuang Siyao for application to special fund programs. These efforts are designed to accelerate the project’s commissioning and early effectiveness, thereby strongly boosting Shijiazhuang Siyao’s growth and strengthening its position in the market.
Officials from other municipal departments and park management authorities also expressed their commitment to firmly upholding the principle that “projects are paramount,” continuing to vigorously optimize the business environment, and taking multiple measures to provide robust support for enterprises. They pledged to pursue breakthroughs in the biopharmaceutical industry with a “nailing-down” spirit, thereby providing strong backing for the city’s economy to surpass the one-trillion-yuan mark and achieve a leapfrog development.
Reprinted from: Shijiazhuang Daily
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license